Impact of Amiodarone Therapy on the Ablation Outcome of Ventricular Tachycardia in Arrhythmogenic Right Ventricular Cardiomyopathy

Figures

• 

  Figure 1. Patient selection in the present study. Patients with ARVC receiving successful CA for ventricular arrhythmia were screened. We enrolled ARVC patients with clinically documented sustained VT, and patients were further categorized into two groups based on their use of amiodarone within the 8 weeks before CA. ARVC = arrhythmogenic right ventricular cardiomyopathy; CA = catheter ablation; VT = ventricular tachycardia.

• 

  Figure 2. An example of electrophysiological and substrate characteristics in a patient “on” amiodarone before CA. Patients with ARVC “on” amiodarone had a longer total activation time and larger areas with abnormal electrograms. The (left panel) showed an endocardial voltage map and activation map with local abnormal electrograms. The (right panel) showed an epicardial voltage map and activation map with local abnormal electrograms (* indicated the location of corresponding signal). “See text for details”.

• 

  Figure 3. An example of electrophysiological and substrate characteristics in a patient “off” amiodarone before CA. The (left panel) showed an endocardial voltage map and activation map with local abnormal electrograms. The (right panel) showed an epicardial voltage map and activation map with local abnormal electrograms (* indicated the location of corresponding signal). “See text for details”.

• 

  Figure 4. Kaplan–Meier curve for ablation outcomes during follow-up. (A) The Kaplan–Meier curve showed the recurrence-free survival in patients “on” and “off” amiodarone. Higher VT/VF recurrences were observed in patients “on” amiodarone than in those “off” amiodarone. (B) The Kaplan–Meier curve demonstrated the VT/VF recurrence-free survival in the patients with or without continuous amiodarone use after the successful ablation in patients “on” amiodarone before CA.